Investing.com - Aptinyx (NASDAQ: APTX) reported first quarter EPS of $-0.180, $0.02 better than the analyst estimate of $-0.204. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Aptinyx (NASDAQ:APTX) reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations. Aptinyx announced...
Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Healthcare, Oil & Gas and Basic Materials sectors led shares higher. At the close in NYSE, the...
Aptinyx (NASDAQ:APTX) reported Q4 EPS of ($0.29), $0.06 better than the analyst estimate of ($0.35). For earnings history and earnings-related data on Aptinyx (APTX) click here.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced...